BioStock: New CEO for Xintela's subsidiary Targinta

Xintela recently achieved an important milestone towards the goal of spinning out its subsidiary Targinta when Per Norlén was recruited as CEO and CMO for the company. Norlén has vast experience in early-stage drug development and antibody-based cancer drugs, which will be very useful in Targinta. BioStock reached out to Per Norlén to hear his thoughts on his mission to lead and develop Targinta.

Read the full article at biostock.se:

https://www.biostock.se/en/new-ceo-for-xintelas-subsidiary-targinta/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se